Renaissance Capital logo

BLSM News

US IPO Weekly Recap: August kicks off with flurry of biotech IPOs

BRVE

Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more

BlossomHill Therapeutics prices upsized IPO at $16, the midpoint of the range

BlossomHill Therapeutics logo

BlossomHill Therapeutics, which is developing small molecule cancer therapies, raised $150 million in an upsized IPO by offering 9.4 million shares at $16, the midpoint of the $15 to $17 range. The San Diego, CA-based company originally filed to offer 7.8...read more

Cancer biotech BlossomHill Therapeutics sets terms for $125 million IPO

BlossomHill Therapeutics logo

BlossomHill Therapeutics, a Phase 2-ready biotech developing small molecule cancer therapies, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17. At...read more

US IPO Week Ahead: August IPO market opens with biotechs, a bank, and SpaceX earnings

SPCX

Updated Monday, 8/3. Six IPOs are currently scheduled for the week ahead, featuring five biotechs and a California bank. Mega-issuer SpaceX (SPCX) will also be in focus as it reports earnings for the first time as a public company ahead of a partial lock-up...read more